New Two-Drug attack on Tough-to-Treat cancers begins human testing
Disease control
Recruiting now
This early-stage trial is testing the safety and initial effectiveness of a new oral drug, STC-15, when given alongside an existing immunotherapy called toripalimab. It will enroll about 188 adults with specific advanced cancers—including lung, melanoma, endometrial, and head/nec…
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC